Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Cleveland, Ohio 44106


RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced solid tumors.

Study summary:

OBJECTIVES: - Determine the pharmacokinetic profile of gemcitabine, doxorubicin HCl liposome, and vinorelbine in patients with advanced solid tumors. - Determine the maximum tolerated dose of this regimen in these patients. - Determine the toxicity profile of this regimen in these patients. OUTLINE: This is a dose escalation study. Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome, gemcitabine, and vinorelbine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for up to 1 year. PROJECTED ACCRUAL: Approximately 9-24 patients will be accrued for this study within 12-18 months.


DISEASE CHARACTERISTICS: - Histologically confirmed solid tumor not amenable to curative surgery, radiotherapy, or chemotherapy - No brain metastases or primary brain tumors PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - At least 12 weeks Hematopoietic: - WBC at least 3,500/mm3 - Absolute neutrophil count at least 1,500/mm3 - Platelet count at least 100,000/mm3 - Hemoglobin greater than 10 g/dL Hepatic: - Bilirubin no greater than 1.2 mg/dL - AST and/or ALT less than 2.5 times upper limit of normal (ULN) - PT no greater than ULN (anticoagulant independent) Renal: - Creatinine no greater than 1.5 mg/dL AND/OR - Creatinine clearance greater than 60 mL/min Cardiovascular: - No New York Heart Association class III or IV heart disease - LVEF at least 45% by MUGA or echocardiogram Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior bone marrow or peripheral blood stem cell transplantation following high dose chemotherapy - At least 3 weeks since prior biologic therapy for cancer and recovered - No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) Chemotherapy: - See Disease Characteristics - See Biologic therapy - No more than 1 prior chemotherapy regimen - No prior vinca alkaloids - Prior anthracycline allowed if total dose no greater than 300 mg/m2 - At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or carmustine) and recovered Endocrine therapy: - At least 3 weeks since prior endocrine therapy for cancer and recovered Radiotherapy: - See Disease Characteristics - No more than 1 prior radiotherapy regimen - At least 4 weeks since prior large field radiotherapy - At least 3 weeks since prior radiotherapy for cancer and recovered Surgery: - Not specified



Primary Contact:

Study Chair
Beth A. Overmoyer, MD, FACP
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Backup Contact:


Location Contact:

Cleveland, Ohio 44106
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.